Vitamin D3 Partly Antagonizes Advanced-Glycation Endproducts-Induced NFκB Activation in Mouse Podocytes

Abstract

Background/Aims: We have previously shown that advanced glycation-endproducts (AGEs) induced NFκB activation in differentiated mouse podocytes. This NFκB activation may contribute to the progression of renal disease and mediation of fibrosis by various mechanisms. This study was undertaken to test whether this detrimental response may be reversed by vitamin D3 or its analogue paricalcitol. Methods: Differentiated mouse podocytes were challenged with glycated bovine serum albumin (AGE-BSA), or non-glycated control BSA (in the presence or absence of various concentrations of vitamin D3 (decostriol, 1α,25-dihydroxyvitamin D3)) or its active analog paricalcitol. Quantitative mRNA expressions were measured by real-time PCR, whereas protein expressions were determined by Western blotting followed by densitometry. Cytoplasmic and nuclear protein expression of the NFκB subunit p65 (Rel A) were determined by Western blotting. Furthermore, the ratio of phosphorylated to non-phosphorylated IκB-α was measured using specific antibodies. Electrophoretic mobility shift assays and a capture ELISA assay were used to assess NFκB transactivation in vitro. In addition, NFκB transactivation was also monitored in HEK-NFκBIA reporter cells using live cell luminometry. Results: Podocytes expressed the receptor for vitamin D. The vitamins did not suppress receptor for AGEs (RAGE) expression; instead, they rather upregulated RAGE. Although vitamin D3 and paricalcitol partly and differentially modified some of the studied parameters, both hormones inhibited AGE-BSA-induced NFκB transactivation, presumably by various mechanisms including the upregulation of IκB-α protein, keeping NFκB sequestered in an inactive state in the cytoplasm. Conclusion: Vitamin D3 or its analog paricalcitol partly prevented AGE-mediated NFκB activation, an important feature of diabetic nephropathy (DN). Whether this in vitro finding is of clinical relevance to prevent/treat DN requires further studies.

Energy metabolism and autism: the ameliorative potential of carnosine and agmatine

“…Deficiency in vitamin-D has also been proposed to play a role in ASD [43][44][45] and it has been claimed that vitamin D supplementation in children may improve symptoms of ASD [46]. It is interesting to note that vitamin D appears to play a role in controlling the reaction between advanced glycation end-products (AGEs) with their cellular receptors (RAGEs) [47][48][49], again observations consistent with the findings of elevated levels of protein glycation in ASD subjects.…”

Native Hypovitaminosis D in CKD Patients: From Experimental Evidence to Clinical Practice

“…Analogous results in the same experimental model have been obtained more recently using a pretreatment with Paracalcitol [62]. The beneficial VDR activation effects on inflammation have been also demonstrated in chronic models of renal diseases such as UUO, diabetes and toxic [63].…”

Effects of vitamin D supplementation on advanced glycation end products signaling pathway in T2DM patients: a randomized, placebo-controlled, double blind clinical trial

“…Furthermore, RAGE expression modulation may improve vascular oxidative stress and alleviate cardiovascular complications [29]. A few studies have detected vitamin D supplementation effect on RAGE expression, which indicates conflicting results in various tissues and cells [30, 31]. Also in this study, vitamin D supplementation for duration of 3 months could significantly reduce TNF-α serum levels.…”